Julie A. Henry is an Enterprise IP Contract Manager in Department of Business Development, Mayo Clinic Ventures at Mayo Clinic in Rochester, Minnesota. Her responsibilities involve collaborating with internal and external customers as a resource to manage unique and complex intellectual property related contractual issues across the entire Mayo enterprise. Additionally is involved in the evaluation, patent strategy and out-licensing of a portfolio of Mayo Clinic inventions. Ms. Henry has been with Mayo Clinic for over twenty five years. She has had experience in all facets of the commercialization process including drafting, negotiating and management of agreements. She has given presentations relating to licensing technologies as well as educating staff concerning intellectual property protection and commercialization. Before taking her position in Mayo Clinic Ventures, Ms. Henry was a Research Technician in the Peptide Synthesis Protein Sequencing Core Facility in Mayo Clinic’s Biochemistry and Molecular Biology Department. Ms. Henry received her B.A. from St. Cloud State University in St. Cloud, Minnesota and her Master of Business Administration from University of St. Thomas in Minneapolis, Minnesota.
Perry Hackett is a co-founder of Recombinetics and serves as Chair of its Scientific Advisory Board. He is co-founder of gene therapy company, Discovery Genomics, where he previously served as Chief Scientific Officer and Chairman. He is also a professor and research scientist in the University of Minnesota’s department of Genetics, Cell Biology and Development and co-founder of the Center for Genome Engineering. Hackett has a degree in Physics from Stanford University, a PhD in Biophysics and Genetics from the University of Colorado, and did postdoctoral training at the Max Planck Institute for Cell Biology in Germany and at the University of California in San Francisco.
J. Fernando Bazan was appointed Chief Technology Officer when he joined BioTechne on August 1, 2013. Following training at Stanford, Berkeley, and UCSF in biochemistry and biophysics, he led very active groups in biotherapeutics discovery as a senior scientist at DNAX Research Institute (now Merck Research Labs) and at Genentech (Roche). He also served as Chief Scientific Officer at NeuroScience, a neuroimmunology diagnostics startup. Dr. Bazan holds an adjunct faculty appointment in the Dept. of Pharmacology at the University of Minnesota School of Medicine.
Pamela York is a serial entrepreneur, early stage investor, and repeat inventor with a track record of success in several industries. Currently she the Co-founder and General Partner of CAPITA3, an early stage venture capital group focused on women-led companies in health sectors. Previously, Pam pioneered and successfully commercialized three technology platforms and co-founded two high tech startups with successful exits – Orchid Cellmark Inc. and Princeton Lightwave Inc. She also led the University of Iowa’s technology commercialization foundation, where she oversaw a portfolio of 1000 technologies concentrated in life sciences, built a startup ecosystem from scratch, and led the formation of 40 technology startups that raised over $150M in follow-on capital with 6 exits totaling $200M to date. She has a PhD in electrical engineering from the University of Illinois, holds numerous patents, and has authored many scientific publications. Pam is a commercial reviewer for the NSF SBIR program, the co-founder of the WEStart.MN movement for women entrepreneurs, a judge for the Minnesota Cup Food & Ag Division, and Board Chair for CoreBiome, a microbiome startup from the University of Minnesota. She is adjunct faculty at the University of Minnesota, teaching the NSF I-CorpsTM Value Proposition Design workshop and Business Formation.
Bryan Clark is an R&D Fellow in Corporate Research at Boston Scientific with over 13 years of experience innovating and commercializing technologies in the medical device industry. His current focus is on identifying and developing new solutions that solve unmet clinical needs and fostering growth in white space areas, including leading partnerships and collaborations with leading institutions around the world and connecting across disciplines to drive innovation in healthcare. He has led numerous projects and partnerships across multiple technology and disease state areas including bioelectric medicine, digital health, cardiovascular disease, pulmonary disease, urological disorders and chronic pain. He additionally leads Boston Scientific’s support for the gBeta Medtech startup accelerator, collaborating with gener8tor and other sponsors to help foster innovation and support entrepreneurs in Minnesota. He holds a Bachelor of Science in Composite Materials Engineering from Winona State University and an MBA from the Carlson School of Management at the University of Minnesota.
As Associate Director of the Holmes Center for Entrepreneurship and Program Director of MIN-Corps, Carla Pavone facilitates technology commercialization by designing and delivering education and coaching to University of Minnesota STEM students, faculty and researchers interested in bringing their innovations to the market. She also teaches entrepreneurship, strategy and leadership courses, primarily at the MBA level. Dr. Pavone has a BA in biology from University of Pennsylvania, an MBA from Harvard Business School, and a PhD in business administration from the Carlson School of Management. She has had three careers: in magazine and software publishing (primarily at start-ups), in financial services (mainly leading internal corporate start-ups and turnarounds) and in academia. She also currently serves on the boards of Social Venture Partners Minnesota and WomenVenture.
Danny J. Cunagin is a co-founder, co-CEO, and managing partner of Invenshure, a venture catalyst company focused on the creation and development of tech and biotech companies built around novel IP from top scientists and institutions. Danny previously served as the CEO and Chief Manager of Steady State Imaging, LLC from 2008 until April 2011 when the company was sold to GE Healthcare. Previously, Danny was the CEO of Logic Product Development, during which time the business grew into one of the largest fully integrated product development-consulting firms in the US. He is currently on the Board of OneOme, Imbio, Exosite, Tychon and Sarisa and manages the biotech franchise of Invenshure. He is the author of two patents, was noted as one of “forty under 40” in 1999 by City Business and has a B.S.M.E. from the University of Kentucky.
Mark is CEO of Vortex Immersion Media, the world’s leading designer of transformative 360 immersive entertainment experiences including; live concerts, stage shows and corporate events featuring surround video and audio, spectacular visual effects and real-time interactivity. Mark spent his early career around Wall Street as principle with Firms such as UBS Paine Webber and Wellington Shields & Co. and has been a guiding force within several start-ups, takeovers, and turn-arounds; Inktomi Corporation (acquired by Yahoo!), Emmy Award winning Teranex (video processing), Mesh Networks (mobile wifi, acquired by Motorola,) Theseus Logic (clock-less semiconductor) Skycross (award-winning antenna technology) Zeros & Ones, Inc. (digital convergence) and ONEHOPE Wine (cause commerce.) Additionally, Mark is an inspirational speaker, producer & Co-Host of The LIFE CHANGES Radio Show and Live Event Series focused on sharing and embracing change in order to "do life better." Having experienced extraordinarily large ups and downs along with all of the life lessons in between, Mark has learned that wisdom is gained through experience. The successes are fun and empowering yet personal growth and expansion comes from the setbacks and struggles. He teaches that this is where the real insightful magic is discovered and authenticity ultimately realized.